Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mpofu, S.
Right arrow Articles by Moots, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mpofu, S.
Right arrow Articles by Moots, R. J.
Related Collections
Right arrow Osteoarthritis and Cartilage
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 1117-1118
© 2003 British Society for Rheumatology

Letters to the Editor

Treatment of respiratory complications in recalcitrant relapsing polychondritis with infliximab

S. Mpofu, C. Estrach, J. Curtis1 and R. J. Moots

Academic Rheumatology Unit and
1 Department of Radiology, University Hospital Aintree, Liverpool, UK

The first 10% of the full text of this article appears below.

SIR, the outcome of relapsing polychondritis (RP) depends on remission of the underlying inflammatory process. Most patients experience a fluctuant inflammatory course, but the disease is generally progressive. Ten per cent of deaths in RP are due to respiratory complications. The optimal therapeutic approach to patients with RP is poorly understood. Corticosteroids are able to suppress disease activity but do not stop disease progression and are associated with side-effects. Various disease-modifying anti-rheumatic drugs have been used in an attempt to achieve a lower dose of steroid or for refractory cases. Infliximab is a monoclonal antibody that binds . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
E. F. Vicente, A. Hernandez-Nunez, J. Aspa, M. Aragues, and R. Garcia-Vicuna
Crohn's disease, relapsing polychondritis and epidermolysis bullosa acquisita: an immune-mediated inflammatory syndrome
Rheumatology, March 1, 2008; 47(3): 380 - 381.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. W. Seymour, D. M. Home, R. O. Williams, and S. A. Allard
Prolonged response to anti-tumour necrosis factor treatment with adalimumab (Humira) in relapsing polychondritis complicated by aortitis
Rheumatology, November 1, 2007; 46(11): 1738 - 1739.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
P. Vounotrypidis, G. T. Sakellariou, D. Zisopoulos, and C. Berberidis
Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra)
Rheumatology, April 1, 2006; 45(4): 491 - 492.
[Full Text] [PDF]